IMRT proves effective mesothelioma treatment, study finds

25 Jul 2017 by under Research/Treatment
Przekrój ciała Pacjenta z rozkładem dawki promieniowania z nowotworem Głowy i Szyji leczonego techniką IMRT. 100x100 IMRT proves effective mesothelioma treatment, study finds

Morelmorel/Wikipedia

Intensity modulated therapy (IMRT) is the most advanced type of radiation, allowing for even greater regulation of radiation beams than was possible in 3D planning. It’s a “sophisticated form of 3D planning,” according to OncoLink, and it is used regularly to treat a variety of cancers, including prostate cancer, gastrointestinal cancers, brain cancers and lung cancers.

IMRT has become increasingly important in the treatment of mesothelioma, a rare cancer caused by asbestos exposure that affects the lining of internal organs, but until recently, its benefits had never been proven, according to Surviving Mesothelioma. Dr. Kenneth Rosenzweig’s new study published in the Annals of Translational Medicine concludes IMRT at an experienced institution has led to improved mesothelioma outcomes and is “both feasible and effective” as a treatment option for

The high doses of radiation are meant to damage cancer cells’ DNA and prevent them from replicating to form tumors. IMRT can conform beams of radiation to the size and shape of mesothelioma tumors, minimizing its harmful effects on healthy tissues. OncoLink reports IMRT specifically allows for radiation beams to be subdivided into different strengths—or modulated—giving rise to the therapy’s name.

“Although treatment planning for IMRT is highly complex, and people with mesothelioma tumors tend to have multiple health problems, as experience with IMRT has increased, pleural mesothelioma outcomes have steadily improved,” Surviving Mesothelioma states.

Doctors and researchers are always on the lookout for new advancements in treating mesothelioma as the cancer has proven especially difficult to treat. On average, patients diagnosed with the disease die within two years of receiving their diagnosis.

 

Comments are closed.